Today's Research: Delcath Systems, Astex Pharma, BioMarin Pharma, and Akorn Editor Note: For more information about this release, please scroll to bottom PR Newswire LONDON, July 18, 2013 LONDON, July 18, 2013 /PRNewswire/ -- On Wednesday, July 17, 2013, shares in the healthcare sector ended mostly lower even as the broader market ended higher following positive news from Federal Reserve Chairman Ben Bernanke. The major movers in the sector included Delcath Systems Inc. (NASDAQ: DCTH), Astex Pharmaceuticals Inc. (NASDAQ: ASTX), BioMarin Pharmaceuticals Inc. (NASDAQ: BMRN), and Akorn Inc. (NASDAQ: AKRX). AAAResearchReports.com has completed their technical analysis on DCTH, ASTX, BMRN, and AKRX and these free reports are accessible by registering at: http://www.aaaresearchreports.com/register/ Shares in Delcath Systems Inc. moved lower on Wednesday, extending their losses for the week. The company's shares ended the day at $0.377, down 0.79%, after oscillating between $0.36 and $0.38. A total of 717,445 shares were traded which is less than its daily average volume of 1.61 million. In the last three months, Delcath's shares have fallen by 73.07% as compared to a gain of 8.31% in the S&P 500. Sign up for free technical research on DCTH at: http://www.AAAResearchReports.com/DCTH071813.pdf Astex Pharmaceuticals Inc.'s stock rose sharply on Wednesday, extending their gains for the week. The company's shares fluctuated between $5.48 and $5.70 before finishing the day 2.93% higher at $5.63. A total of 1.24 million shares were traded which is below the daily average volume of 1.57 million. Astex's shares have now gained 15.37% in the last one month, thus outperforming the S&P 500. However, in the last three months, the stock has fallen by 9.49%. Be sure to read our latest technical research on ASTX by registering at: http://www.AAAResearchReports.com/ASTX071813.pdf Shares in BioMarin Pharmaceuticals Inc. edged lower on Wednesday even as the broader market ended higher. The company's shares oscillated between $62.42 and $63.39 before closing the session 0.30% lower at $62.64. A total of 566,476 shares were traded which is less than its daily average volume of 1.38 million. The company's shares have gained 7.68% in the last one month as compared to a gain of 2.55% in the S&P 500. The stock has fallen by 3.35% and 1.63% in the last three trading sessions and the last three months, respectively, thus underperforming the S&P 500. Sign up and read the complimentary report on BMRN at: http://www.AAAResearchReports.com/BMRN071813.pdf Akorn Inc.'s stock closed 4.07% lower on Wednesday at $13.43 after fluctuating between $13.40 and $14.05. A total of 544,543 shares were traded which is slightly above the daily average volume of 541,382. The company's shares have fallen by 0.67% in the last one month, and 5.95% in the last three months, thus underperforming the S&P 500. The free report on AKRX can be downloaded by signing up now at: http://www.AAAResearchReports.com/AKRX071813.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE AAA Research Reports Contact: AAAresearchreports.com Phone #: +1(646)396-9126
Today's Research: Delcath Systems, Astex Pharma, BioMarin Pharma, and Akorn
Press spacebar to pause and continue. Press esc to stop.